Free tool
FAERS Monitor: Cleocin Hydrochloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050162 or its brand name (Cleocin Hydrochloride, Clindamycin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
3,695
Serious
2,818
76% of reports
Hospitalization
1,395
Death reported
243
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea293
- rash278
- nausea258
- off label use257
- pain232
- dyspnoea212
- drug ineffective211
- drug hypersensitivity197
- headache181
- pruritus179
- fatigue168
- arthralgia158
- cough142
- pyrexia131
- vomiting131
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 34 |
| 2005 | 80 |
| 2006 | 52 |
| 2007 | 43 |
| 2008 | 55 |
| 2009 | 50 |
| 2010 | 44 |
| 2011 | 61 |
| 2012 | 91 |
| 2013 | 40 |
| 2014 | 28 |
| 2015 | 51 |
| 2016 | 123 |
| 2017 | 83 |
| 2018 | 105 |
| 2019 | 153 |
| 2020 | 173 |
| 2021 | 224 |
| 2022 | 444 |
| 2023 | 440 |
| 2024 | 537 |
| 2025 | 462 |
| 2026 | 322 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,464 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug hypersensitivitySignal | 197 | 5.8 | 5.1 | 784 |
| rashSignal | 278 | 3.6 | 3.2 | 538 |
| coughSignal | 142 | 2.9 | 2.5 | 175 |
| pruritusSignal | 179 | 2.7 | 2.3 | 186 |
| diarrhoeaSignal | 293 | 2.6 | 2.3 | 292 |
| arthralgiaSignal | 158 | 2.2 | 1.9 | 100 |
| pyrexiaSignal | 131 | 2.2 | 1.8 | 81 |
| painSignal | 232 | 2.2 | 1.9 | 146 |
| dyspnoeaSignal | 212 | 2.1 | 1.9 | 130 |
| nausea | 258 | 1.9 | 1.6 | 105 |
| off label use | 257 | 1.7 | 1.5 | 72 |
| headache | 181 | 1.6 | 1.4 | 46 |
| vomiting | 131 | 1.6 | 1.3 | 28 |
| fatigue | 168 | 1.2 | 1.1 | 7 |
| drug ineffective | 211 | 0.9 | 0.8 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.